Figure 4. Zeb1 regulates HSC self-renewal and differentiation in a cell-autonomous manner.

(A) Schematic of secondary HSC transplantation. 300 CD45.2⁺ HSCs from primary recipients from control or Zeb1^–/– mice mixed with 3 × 10⁵ BM competitor cells (CD45.1) were transplanted into lethally irradiated recipients (CD45.1), and the mice were analyzed at week 12. (B) Percentage of donor cells in PB and donor contribution to myeloid (MAC1⁺), B (B220⁺), and T (CD4⁺/CD8⁺) cells at week 12 after secondary HSC transplantation from control (n = 7) and Zeb1^–/– (n = 5) from 2 independent experiments. (C) Schematic of the secondary total BM transplantation in cell-autonomous manner. 5 × 10⁵ CD45.2⁺ BM cells from primary recipients 14 days after the last pIpC dose from control or Zeb1^–/– mice mixed with 5 × 10⁵ BM competitor cells (CD45.1) were transplanted into lethally irradiated recipients (CD45.1), and the mice were analyzed at week 16. (D) Percentage of donor cells in PB and BM at week 16 after secondary cell autonomous total BM transplantation from control (PB n = 5, BM = 6) and Zeb1^–/– (PB n = 7, BM = 6) mice from 1 experiment. (E) Donor contribution to PB MAC1⁺ myeloid cells, B220⁺ B cells, and CD4⁺/CD8⁺ T cells at week 16 after secondary cell-autonomous total BM transplantation from control (n = 5) and Zeb1^–/– (n = 7) mice from 1 experiment. Error bars show mean ± SEM. Mann-Whitney U test was used to calculate significance. *P < 0.05; **P < 0.01.